# R1 CLINICAL-SAFETY REVIEW — adult_t_cell_leukemia_lymphoma

APPROVE

Verdict: APPROVE. Clinically safe, grounded, dose-free, and appropriately scoped as decision-support.
Goldens changed: no (intended: n/a — narrative/KB content, not engine logic).
No .verdict.md existed at the sidecar path; reviewed the draft directly.

## 1. SAFETY — pass
- No absolute/directive statements that could harm a clinician who followed them. Consistent hedging ("generally directed toward", "investigational", "only potentially curative ... despite limited success").
- Subtype-first framing (acute/lymphomatous/chronic/smoldering = Shimoyama) is the correct organizing principle and is stated as such rather than a rigid rule.
- Two genuine safety signals are surfaced correctly and are the kind of thing that prevents harm:
  - Mogamulizumab before alloSCT -> severe treatment-refractory GVHD (Treg depletion) with sequencing caution.
  - Alemtuzumab -> near-universal CMV antigenemia requiring proactive monitoring.
  - Hypercalcemia (PTHrP/TGF-beta/RANKL) monitoring, and opportunistic-infection prophylaxis (PCP, cryptococcus, strongyloides, disseminated zoster).
- Minor, non-blocking nuance: the meta-analysis line notes antiviral (AZT/IFN) benefit "as well as in acute disease," while the acute-subtype section correctly directs intensive multiagent chemo (JCOG9801-type). This mirrors the real tension in the literature and is not presented as a treatment instruction for acute disease, so it is not unsafe. Could be tightened but is accurate.

## 2. GROUNDING — pass
All treatment claims are consistent with DeVita 12th ed / NCCN standard of care. Nothing fabricated or outdated:
- AZT + IFN-alpha for indolent (smoldering/chronic) and the retrospective/meta-analysis basis — grounded.
- Chemotherapy favored for lymphomatous type in the same analysis — grounded.
- Acute: phase III intensive alternating vs dose-dense CHOP + IT MTX, higher CR and better 3-yr OS, ORR not significantly different, OS still poor — grounded (JCOG9801, VCAP-AMP-VECP), described without naming the regimen constituents.
- Mogamulizumab (anti-CCR4) ORR ~50% / short PFS ~5 mo in relapsed disease — grounded phase II.
- Lenalidomide limited activity; alemtuzumab activity with CMV toxicity — grounded.
- No mis-attribution to DeVita: every claim that is general-oncology standard rather than DeVita's ATLL section is explicitly self-labelled (alloSCT "only potentially curative"; local RT for symptomatic sites; surgery/RT absence). This satisfies the adversarial rule even without a verdict file.

## 3. DOSE-FREE — pass
No mg, mg/m2, AUC, or numbered schedules. The numerics present are outcome/epidemiology figures (3-year OS, ~50% ORR, ~5-month PFS), not dosing. Regimen constituents explicitly deferred to structured protocol templates.

## 4. SCOPE — pass
Framed as decision-support: subtype-specific selection deferred to heme-onc experienced in T-cell malignancies, targeted agents labelled investigational/evolving, transplant sequencing described as a decision rather than a mandate. "When to refer" is appropriate.

## 5. ADVERSARIAL FLAGS
No .verdict.md to reconcile. The draft pre-empts the usual scope-creep/mis-sourcing traps by tagging non-DeVita claims as general standard.

No Critical, Important, or Advisory blocking items.
